CDER’s current proposal to withdraw the accelerated acceptance of Makena (HPC) was based mostly upon a big randomized trial that failed to substantiate the advantage of this drug to newborns or lower the chance of PTB. In creating the choice to propose Makena’s withdrawal, CDER also reviewed effects from prior research of progestins (HPC alon